Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01 | Zendy

B. Vera | Zendy; Naiara Martínez-Vélez | Zendy; Enric Xipell | Zendy; Arlet Acanda de la Rocha | Zendy; Ana Patiño-Garcı́a | Zendy; Javier S. Castresana | Zendy; Marisol González-Huarriz | Zendy; Manel Cascalló | Zendy; Ramón Alemany | Zendy; Marta M. Alonso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01

Author(s) -

B. Vera,

Naiara Martínez-Vélez,

Enric Xipell,

Arlet Acanda de la Rocha,

Ana Patiño-Garcı́a,

Javier S. Castresana,

Marisol González-Huarriz,

Manel Cascalló,

Ramón Alemany,

Marta M. Alonso

Publication year - 2016

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0147211

Subject(s) - oncolytic virus , glioma , oncolytic adenovirus , in vivo , cancer research , medicine , oncology , biology , tumor cells , microbiology and biotechnology

Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro . In vivo , in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research